Expression of Yo Antigen in a Prostatic Adenocarcinoma.

Can J Neurol Sci

6CRMR NAF et autres Neuropathies RaresService de Neurologie,CHU Bicêtre78 rue du Général Leclerc94270 Le Kremlin-Bicêtre,France.

Published: March 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2016.400DOI Listing

Publication Analysis

Top Keywords

expression antigen
4
antigen prostatic
4
prostatic adenocarcinoma
4
expression
1
prostatic
1
adenocarcinoma
1

Similar Publications

Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy.

Front Immunol

September 2025

Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.

Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.

Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.

View Article and Find Full Text PDF

Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.

Front Immunol

September 2025

Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

Gliomas are the most common primary malignant tumors of the central nervous system (CNS), and despite progress in molecular diagnostics and targeted therapies, their prognosis remains poor. In recent years, immunotherapy has emerged as a promising treatment modality in cancer therapy. However, the inevitable immune evasion by tumor cells is a key barrier affecting therapeutic efficacy.

View Article and Find Full Text PDF

The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor-positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.

View Article and Find Full Text PDF

Objectives: Lymph node metastasis (LNM) is an important factor affecting the stage and prognosis of patients with lung adenocarcinoma. The purpose of this study is to explore the predictive value of the stacking ensemble learning model based on F-FDG PET/CT radiomic features and clinical risk factors for LNM in lung adenocarcinoma, and elucidate the biological basis of predictive features through pathological analysis.

Methods: Ninety patients diagnosed with lung adenocarcinoma who underwent PET/CT were retrospectively analyzed and randomly divided into the training and testing sets in a 7:3 ratio.

View Article and Find Full Text PDF

Plasma samples obtained approximately 3 ( = 100) and 12 months ( = 78) after acute SARS-CoV-2 infection were tested for S1, spike, and N antigens. There were no significant differences in plasma proteins or single-cell protein expression levels on immune cells between those with and without plasma antigen detected.

View Article and Find Full Text PDF